The STAT family of transcription factors transduce signals from cytokine receptors to the nucleus where STAT dimers bind to DNA and regulate transcription. STAT3 is the most ubiquitous of the STATs being activated by a wide variety of cytokines and growth factors. STAT3 has many roles in physiological processes such as inflammatory signalling, aerobic glycolysis, and immune suppression and was also the first family member shown to be aberrantly activated in a wide range of both solid and liquid tumours. STAT3 promotes tumourigenesis through regulating the expression of various target genes including cell cycle regulators, angiogenic factors and anti-apoptosis genes. Paradoxically, in some circumstances STAT3 signalling induces cell death. The best known example is the involuting mammary gland where STAT3 is essential for the induction of a lysosomal pathway of cell death.
Introduction
The signal transducers and activators of transcription (STATs) are a family of seven proteins of close homology, STAT1, STAT2, STAT3, STAT4, STAT5a and closely related STAT5b, and STAT6. There are four known isoforms of human STAT3 located on chromosome 17q21.31 (1) . STAT3α, the predominantly expressed isoform, is a 770 amino acid, 88kDa protein that elicits most functions ascribed to STAT3 (2) .
STAT3β, an alternatively spliced variant, lacks the C-terminal domain and was described as a dominant negative form until evidence showed it to be a functional transcription factor (3). STAT3γ and STAT3δ, the lesser well known STAT3 isoforms, may have roles in neutrophil and granulocytic differentiation respectively (4, 5) . The structure of STAT3 is typical of the STAT family, comprising an Nterminal domain, a coiled-coil domain, a Src homology 2 (SH2) domain, a DNA binding domain and a C-terminal transactivation domain ( Figure 1 ) (6) . The Nterminal coiled-coiled domain forms an interface for dimer-dimer interactions during STAT3-driven initiation of gene expression (7, 8) . The SH2 domain contains three important solvent accessible subpockets that stabilize STAT-STAT dimer interactions and STAT3-receptor binding interactions (9) . The DNA-binding domain provides the protein-DNA binding interface, whereby upon activation, individual STAT monomers dimerize completing a nutcracker-like structure which binds to specific DNA motifs, initiating transcription (10).
STAT3 activation
STAT3 activation is mediated primarily by IL-6 family cytokine receptor-associated Janus kinases (JAKs) although receptor tyrosine kinases such as EGFR and nonreceptor tyrosine kinases such as Src can also phosphorylate STAT3 ( Figure 2 ) (11) (12) (13) . Following JAK activation, latent cytosolic STAT3 monomers dock with cytokine-bound receptors at pTyr sites through SH2 domain binding, whereupon
JAKs phosphorylate STAT3 on a conserved tyrosine residue (pTyr705) found in the C-terminal region. Post-phosphorylation, STAT3 monomers dissociate from receptor docking sites and dimerize through reciprocal pTyr and SH2 domain interactions (14) .
STAT3 is known to form homo and heterodimers with STAT1 due to the high sequence similarity between the two proteins, diversifying the number of genes under their transcriptional control (15) . STAT3 can also be further modified by phosphorylation on a serine residue (S727) in the C-terminal region to promote full STAT3 activation. This serine residue, important in prolonging retention in the nucleus and affecting overall growth, is only present on the STAT3α isoform (16, 17) . STAT3 can also be acetylated at Lys685 to alter expression of specific gene targets (18).
STAT3 regulation
STAT3 dimers regulate transcription of a variety of genes through binding to canonical palindromic CCT(N) 3 GAA sites in the promoter regions of target genes.
Collectively, each STAT member elicits a wide range of important cellular responses and although DNA binding sites appear to be shared, each STAT displays specific gene expression signatures that seem to be cell type dependent (19) . Expression and activation of STAT3 is exquisitely regulated in normal cells with a plethora of factors that silence JAK/STAT signalling. These include SOCS (suppressor of cytokine signalling) proteins that can bind to activated JAKs or receptor domains and efficiently block STAT phosphorylation. SOCS3 is a direct transcriptional target of STAT3, providing a cellular negative feedback mechanism for STAT3 signalling (20) . The PIAS family (protein inhibitor of activated STAT) are a family of SUMO-E3 ligases that covalently attach SUMO proteins to target substrates, thus altering their activity. PIAS3 in particular has been shown to directly inhibit STAT3 activity through this post translational modification (21) . In addition to these, PTPs (protein tyrosine phosphatases), SHPs (Src homology domain-containing tyrosine phosphatases) and the more recently discovered PTPRT (protein tyrosine phosphatase receptor T) can specifically dephosphorylate STAT3 and upstream kinases in the JAK-STAT pathway to terminate STAT3 signalling (22).
STAT3 as an oncogene
STAT3 was first noted to be constitutively active in breast cancers (23) . It became directly associated with oncogenic signalling when cells transformed by HTLV-1 and EBV viral infections were found to have constitutive STAT3 activity, a result of increased tyrosine kinase activity (24, 25) . Furthermore, blocking STAT3 activity decreases cellular transformation in v-Src transformed cell lines (26) . Further evidence that STAT3 is an oncogene was provided by expressing a mutated STAT3 construct (STAT3C), that constitutively forms dimers, in normal mouse fibroblasts which, when transplanted into nude mice, formed tumours (27) . This STAT3C construct was found to drive tumour formation in a variety of cell types by upregulating important oncogenic and angiogenic factors such as MMP-9, VEGF, and Cten (28) (29) (30) .
During tumourigenesis, STAT3 activity can become dysregulated, despite the impressive array of negative regulators of STAT3 signalling. Abnormal persistent STAT3 activity has been demonstrated in multiple haematological and solid cancers (31) . Of notable interest, constitutive STAT3 activity is found in a high percentage of triple negative breast cancers and in 30-60% of all primary breast cancers (32) .
Unlike most oncogenes, STAT3 mutations that contribute to aberrant STAT3 signalling are not frequently found in tumours. A rare exception is the STAT3 SH2 domain somatic mutations that were found in 12% of inflammatory hepatocellular adenomas that lacked mutations in the IL-6 receptor, which sensitized STAT3 proteins to activation and homo-dimerization independently of IL-6 (33). In the majority of cases, however, persistent STAT3 activation occurs through deregulated upstream signalling where kinases that phosphorylate STAT3 can become overexpressed or constitutively activated (32, 34) .
The primary distinction between STAT3 activation in normal and cancer cells is the level and duration of signalling. While cytokine-mediated activation of STAT3 is substantial and acute, oncogene-mediated STAT3 activation is generally at a lower level and prolonged (35) . Some cancers become dependent upon, or addicted to this activity such that STAT3 inhibition restricts tumour growth and can induce cell death (36) . In addition to the tumour cells themselves, STAT3 activity in the tumour microenvironment plays a major role in tumour progression and metastasis. STAT3 is also implicated in epithelial-to-mesenchymal transition (EMT) which can contribute to invasion and metastasis. Transcription factors known to promote EMT, such as Twist and Snail are up regulated in cancers with aberrant STAT3 activity and STAT3 is required for TGF-β-induced EMT (52, 53) . Consequently, STAT3 inhibition reduces expression of these genes leading to reduced cancer cell invasion (53) . Finally, persistent STAT3 signalling also directs cancer cells towards aerobic glycolysis, increasing proliferation and survival (54) . Taken together, it is clear that STAT3 is implicated in multiple features of cancer cells highlighting the unmet need for effective inhibitors.
In this context it is interesting to note that STAT3 inhibition in adult mice and recent human trials produced only moderate side effects in differentiated tissues suggesting that STAT3 drugs may not be highly toxic and encouraging the further development of STAT3 therapeutics (51, 55, 56) . In addition, STAT3 inhibition sensitizes cancer cells to chemotherapeutic agents, highlighting the potential for STAT3 inhibitors in combinational cancer therapy (57, 58) . However, STAT3 inhibitors need to be able to distinguish between STAT3 and STAT1 to be useful in a clinical setting. STAT3 and STAT1, although structurally very similar, display key differences in transcriptional targets. STAT1 provides an important anti-viral mechanism and is also a known tumour suppressor (59, 60). 
Strategies for inhibiting

Directly inhibiting STAT3
Despite persistent attempts by many laboratories and pharmaceutical companies to develop STAT3 inhibitors, this has yet to be satisfactorily achieved raising the question of whether STAT3 is truly a druggable target. Many direct STAT3 inhibitors have been identified or produced using a variety of techniques, including screens of large compound libraries, computer assisted virtual screening with the STAT3 crystal structure, optimization of natural STAT3 inhibitor compounds and STAT3-binding peptides, and fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD) (75) (76) (77) . These inhibitors can be placed into three broad groups; peptides, small molecules and oligonucleotides. All groups act on Thus, there are a number of STAT3 domains that are potentially targetable by therapeutics and these will be discussed in more detail below.
Targetable STAT3 Domains
The N-terminal domain
The N-terminal coiled-coil domain interface is formed of 4 helices that are grouped to form a hook-like structure and is responsible for protein-protein interactions and formation of multiple oligomers (82) . Here, two STAT3 DNA-bound dimers interact to form a transcription initiating tetramer (7, 8) . In addition this region is required for successful nuclear shuttling of phosphorylated and unphosphorlyated STAT3 monomers (83) . ST3-H2A2, a synthetic peptide discovered from a library directed towards STAT3 N-Domain binding, successfully binds at this site to specifically inhibit STAT3 function but not that of STAT1. The N-Domain of STAT1 displays considerable differences in sequence to STAT3, and therefore is not recognised by the tailored peptide. ST3-H2A2 modified regulation of STAT3 gene targets, increasing expression of 17 pro-apoptotic genes and inducing apoptosis (84) . Furthermore, ST3-H2A2 could be made more membrane permeable by tagging the C-terminus to Penetratin, a 16 amino acid peptide internalized by cells (85).
The SH2 domain
The STAT3 SH2 domain is a 100 amino acid sequence containing three solventavailable subpockets that can interact with activated receptors and a second STAT3 monomer (9, 82) . These pockets interact with key sites, the pTyr-705, the adjacent leucine residue and additional hydrophobic residues on a second STAT3 monomer to stabilize STAT3 dimer interactions. STAT3 SH2 domain inhibitors prevent docking with receptors and dimerization, thereby blocking activation and function (9) . Many 
Why have STAT3 inhibitors not reached the clinic?
Despite these achievements the question remains as to why no STAT3 inhibitors have reached the clinic. Peptide therapeutics, although specific and highly potent, suffer from rapid degradation and instability, although considerable progress has been made into improving peptide pharmacokinetic and pharmacodynamic profiles (91) . SH2 domain binding peptidomimetics also require phosphorylated tyrosine residues to bind to the STAT3 SH2 domain, an essential negative charge that limits cell membrane penetrance, drastically reducing efficacies in vitro and in vivo (47) . Poor membrane permeability can also be improved however, by the addition of membrane translocating sequences or further modification (47, 85) . Modified STAT3 specific
peptides may yet provide a viable option for targeting STAT3 in vivo, although as yet, the aforementioned limitations has meant that none have moved into clinical trials. In contrast, small molecules efficiently cross the membrane. However, FDA-approved small molecule inhibitors are dominated by kinase inhibitors that mimic the structure of ATP and bind the deep hydrophobic ATP binding cleft, a site that STAT3 lacks.
The three inhibitory sites mentioned above are large, planar surfaces that prove difficult for small molecules to bind to specifically and block the large protein-protein interactions. Many small molecule "STAT3 inhibitors", identified from virtual and high-through-put screens, displayed unsaturated ketone groups that can be responsible for forming non-specific bonds with nucleophilic groups of peptides (92) . Membrane permeability and tissue specific delivery have remained problematic for all oligonucleotide therapies however, and has thus limited clinical use (96).
STAT3 therapeutics: future perspectives
Evidence continues to accumulate that STAT3 is an oncogene and an important target for therapy. to the armamentarium in the fight against therapy-resistant cancer will always justify the resources and effort required to develop a STAT3 specific therapeutic.
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